Indian Pharmacopoeia Commission Inaugurates 5th National Pharmacovigilance Week Focused on Patient Safety
SDG 3: Good Health and Well-being | SDG 16: Peace, Justice & Strong Institutions
Institutions: Ministry of Health & Family Welfare
The Indian Pharmacopoeia Commission (IPC), acting as the National Coordination Centre for the Pharmacovigilance Programme of India (PvPI), launched the 5th National Pharmacovigilance Week (17-23 September 2025) under the theme βYour Safety, Just a Click Away: Report to PvPI.β The initiative aims to raise awareness about adverse drug reaction (ADR) reporting among healthcare professionals, regulators, researchers, and the public via simplified digital tools.
During the inauguration, the Drugs Controller General of India (DCGI) noted that India now ranks among the top global contributors in adverse event reporting. The campaign also introduced new awareness measures and improved reporting mechanisms to encourage wider participation in pharmacovigilance.
Strengthening pharmacovigilance is critical for health system resilience and public trust. By enhancing ADR reporting systems and awareness, the government can better monitor drug safety, identify risks early, and inform regulatory actions.
The Indian Pharmacopoeia Commission (IPC) is an autonomous institution under the Ministry of Health & Family Welfare. IPC is responsible for publishing the Indian Pharmacopoeia (IP) - the official book of standards for the quality of drugs and pharmaceuticals in India. IPC manages pharmacovigilance, research and reference standards and provides scientific advice to the DCGI and other regulatory agencies.
Relevant Question for Policy Stakeholders:
How can the Ministry of Health & Family Welfare, state regulatory bodies, and healthcare institutions ensure sustained engagement and systemic integration of ADR reporting into routine clinical practice across public and private sectors?
Follow the full news here: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2167578